{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:18:21Z","timestamp":1792603101251,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T00:00:00Z","timestamp":1545177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostate International"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.prnil.2018.12.002","type":"journal-article","created":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T12:58:44Z","timestamp":1545915524000},"page":"83-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Photodynamic therapy for prostate cancer: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"7","author":[{"given":"Lang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanfeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prnil.2018.12.002_bib1","first-page":"7","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.prnil.2018.12.002_bib2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.clon.2013.05.002","article-title":"Focal therapy for prostate cancer: rationale and treatment opportunities","volume":"25","author":"Kasivisvanathan","year":"2013","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"4","key":"10.1016\/j.prnil.2018.12.002_bib3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.pdpdt.2015.10.001","article-title":"Treatment of localized prostate cancer using WST-09 and WST-11 mediated vascular targeted photodynamic therapy \u2013 a review","volume":"12","author":"Kawczyk-Krupka","year":"2015","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"3","key":"10.1016\/j.prnil.2018.12.002_bib4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jphotobiol.2004.09.013","article-title":"Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapy","volume":"79","author":"Zhu","year":"2005","journal-title":"J Photochem Photobiol B"},{"issue":"18","key":"10.1016\/j.prnil.2018.12.002_bib5","doi-asserted-by":"crossref","first-page":"30524","DOI":"10.18632\/oncotarget.15496","article-title":"Photosensitizers in prostate cancer therapy","volume":"8","author":"Gheewala","year":"2017","journal-title":"Oncotarget"},{"issue":"8723","key":"10.1016\/j.prnil.2018.12.002_bib6","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/0140-6736(90)92626-S","article-title":"Photodynamic therapy of localized prostatic cancer","volume":"336","author":"Windahl","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.prnil.2018.12.002_bib7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.comppsych.2015.05.001","article-title":"Prevalence of suicide attempts among Chinese adolescents: a meta-analysis of cross-sectional studies","volume":"61","author":"Hu","year":"2015","journal-title":"Compr Psychiatry"},{"key":"10.1016\/j.prnil.2018.12.002_bib8","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/ije\/dys041","article-title":"Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews","volume":"41","author":"Turner","year":"2012","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.prnil.2018.12.002_bib9","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.prnil.2018.12.002_bib10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(16)30661-1","article-title":"Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomized controlled trial","volume":"18","author":"Azzouzi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.prnil.2018.12.002_bib11","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2012.11.057","article-title":"Morbidity of focal therapy in the treatment of localized prostate cancer","volume":"63","author":"Barret","year":"2013","journal-title":"Eur Urol"},{"issue":"4 Pt 1","key":"10.1016\/j.prnil.2018.12.002_bib12","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0022-5347(05)64466-7","article-title":"Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study","volume":"168","author":"Nathan","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.prnil.2018.12.002_bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1078\/1615-1615-00092","article-title":"Photodynamic therapy by means of 5-ALA induced PPIX in human prostate cancer \u2013 preliminary results","volume":"18","author":"Zaak","year":"2003","journal-title":"Med Laser Appl"},{"issue":"1\u20132","key":"10.1016\/j.prnil.2018.12.002_bib14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1615\/JEnvironPatholToxicolOncol.v25.i1-2.230","article-title":"Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer","volume":"25","author":"Verigos","year":"2006","journal-title":"J Environ Pathol Toxicol Oncol"},{"issue":"5","key":"10.1016\/j.prnil.2018.12.002_bib15","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/lsm.20341","article-title":"Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer","volume":"38","author":"Du","year":"2006","journal-title":"Lasers Surg Med"},{"issue":"5","key":"10.1016\/j.prnil.2018.12.002_bib16","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/lsm.20275","article-title":"Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer","volume":"38","author":"Moore","year":"2006","journal-title":"Lasers Surg Med"},{"issue":"5","key":"10.1016\/j.prnil.2018.12.002_bib17","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/j.1464-410X.2008.07753.x","article-title":"Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses","volume":"102","author":"Trachtenberg","year":"2008","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.prnil.2018.12.002_bib18","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00428-013-1454-9","article-title":"Histopathology of prostate tissue after vascular-targeted photodynamic therapy for localized prostate cancer","volume":"463","author":"Eymerit-Morin","year":"2013","journal-title":"Virchows Arch"},{"issue":"6","key":"10.1016\/j.prnil.2018.12.002_bib19","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bju.12816","article-title":"Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy","volume":"116","author":"Moore","year":"2014","journal-title":"BJU Int"},{"issue":"7","key":"10.1016\/j.prnil.2018.12.002_bib20","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00345-015-1505-8","article-title":"TOOKAD\u00ae Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer","volume":"33","author":"Azzouzi","year":"2015","journal-title":"World J Urol"},{"issue":"7","key":"10.1016\/j.prnil.2018.12.002_bib21","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00345-015-1493-8","article-title":"Feasibility, safety, and efficacy of salvage radical prostatectomy after Tookad\u00ae Soluble focal treatment for localized prostate cancer","volume":"33","author":"Lebdai","year":"2015","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.prnil.2018.12.002_bib22","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.juro.2016.05.113","article-title":"Final results of a phase I\/II multicenter trial of WST11 vascular targeted photodynamic therapy for hemi-ablation of the prostate in men with unilateral low risk prostate cancer performed in the United States","volume":"196","author":"Taneja","year":"2016","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.prnil.2018.12.002_bib23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.juro.2017.03.119","article-title":"Vascular targeted photodynamic therapy with padeliporfin for low risk prostate cancer treatment: midterm oncologic outcomes","volume":"198","author":"Lebdai","year":"2017","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.prnil.2018.12.002_bib24","doi-asserted-by":"crossref","first-page":"511","DOI":"10.4103\/1008-682X.123672","article-title":"Perspectives on the clinical management of localized prostate cancer","volume":"16","author":"Nelson","year":"2014","journal-title":"Asian J Androl"},{"issue":"5","key":"10.1016\/j.prnil.2018.12.002_bib25","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nrc1071","article-title":"Photodynamic therapy for cancer","volume":"3","author":"Dolmans","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.prnil.2018.12.002_bib26","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s13244-014-0359-8","article-title":"Post-treatment MRI aspects of photodynamic therapy for prostate cancer","volume":"5","author":"Kulik","year":"2014","journal-title":"Insights Imaging"},{"issue":"2","key":"10.1016\/j.prnil.2018.12.002_bib27","doi-asserted-by":"crossref","first-page":"e006805","DOI":"10.1136\/bmjopen-2014-006805","article-title":"Evaluating variation in use of definitive therapy and risk-adjusted prostate cancer mortality in England and the USA","volume":"5","author":"Sachdeva","year":"2015","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.prnil.2018.12.002_bib28","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.urolonc.2013.10.014","article-title":"Target ablation \u2013 image-guided therapy in prostate cancer","volume":"32","author":"Marien","year":"2014","journal-title":"Urol Oncol"},{"issue":"7","key":"10.1016\/j.prnil.2018.12.002_bib29","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.acuro.2013.12.006","article-title":"Focal therapy for prostate cancer. Alternative treatment","volume":"38","author":"G\u00f3mez-Veiga","year":"2014","journal-title":"Actas Urol Esp"},{"issue":"10","key":"10.1016\/j.prnil.2018.12.002_bib30","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1039\/c5pp00132c","article-title":"Photodynamic therapy (PDT) of cancer: from local to systemic treatment","volume":"14","author":"D\u0105browski","year":"2015","journal-title":"Photochem Photobiol Sci"}],"container-title":["Prostate International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2287888218301387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2287888218301387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:00:21Z","timestamp":1762419621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2287888218301387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S2287888218301387"],"URL":"https:\/\/doi.org\/10.1016\/j.prnil.2018.12.002","relation":{},"ISSN":["2287-8882"],"issn-type":[{"value":"2287-8882","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Photodynamic therapy for prostate cancer: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Prostate International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prnil.2018.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Asian Pacific Prostate Society, Published by Elsevier Korea LLC.","name":"copyright","label":"Copyright"}]}}